SCHEMBL527317

SCHEMBL527317

COc1cc(/C=C/C(=O)OCCC(C)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C)cc(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 14/20 0.51
ABCG2 Q9UNQ0 13/20 0.51
ABCC1 P33527 13/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.51
ALOX5 P09917 1/20 0.49
MET P08581 1/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
HTR1A P08908 1/20 0.47
HPGD P15428 1/20 0.47
HTR2C P28335 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL527316 1.00 ABCB1 (0.51) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL1685990 0.88 ALOX5 (0.49) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL647485 0.85 KDM4E (0.52) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL646615 0.85 KDM4E (0.52) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL6139815 0.83 LMNA (0.43) ABCB1ABCG2ABCC1ALDH1A1LMNA
SCHEMBL645500 0.83 ABCB1 (0.56) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL9440564 0.82 ABCB1 (0.58) ABCB1ABCG2ABCC1ALOX5
SCHEMBL16240911 0.81 KDM4E (0.50) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL16240912 0.81 KDM4E (0.50) ABCB1ABCG2ABCC1KDM4EALDH1A1
SCHEMBL9119693 0.80 KDM4E (0.51) ABCB1ABCG2ABCC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9227351-A None JP disclosed
EP-4655366-A1 A FRAGRANCE COMPOSITION Symrise AG (DE) 2025-12-03 EP disclosed
US-20250326984-A1 FRAGRANCES WITH CYCLOPROPYL STRUCTURE SYMRISE AG (DE) 2025-10-23 US disclosed
EP-4602141-A1 A FRAGRANCE MIXTURE (VI) Symrise AG (DE) 2025-08-20 EP disclosed
US-20250195384-A1 COSMETIC SHISEIDO COMPANY, LTD. (JP) 2025-06-19 US disclosed
WO-2025051340-A1 TRPM8 MODULATORS AND RELATED METHOD FOR MODULATING TRPM8 RECEPTORS SYMRISE AG (DE) 2025-03-13 WO disclosed
EP-4519403-A1 A FRAGRANCE MIXTURE (V) Symrise AG (DE) 2025-03-12 EP disclosed
EP-4516284-A1 COSMETIC Shiseido Company, Ltd. (JP) 2025-03-05 EP disclosed
EP-3547990-B1 SUNSCREEN COMPOSITION COMPRISING NANOCRYSTALLINE CELLULOSE ANOMERA INC (CA) 2025-02-19 EP disclosed
EP-4472606-A1 COMPOSITIONS (III) Symrise AG (DE) 2024-12-11 EP disclosed
US-6544966-B1 Administering a lysophospholipid having one C14-22 fatty acid ester derived from soybeans; used in the fields of cosmetics and dermatology. SHISEIDO COMPANY, LTD. (JP) 2003-04-08 US disclosed
EP-1281396-A2 Skin vitalizing composition for external use anti-aging preparation SHISEIDO COMPANY LIMITED (JP) 2003-02-05 EP disclosed
US-20020045941-A1 Artificial skin and method for evaluating UV screening agent by use of the same SHISEIDO COMPANY, LTD. 2002-04-18 US disclosed
EP-1156074-A1 Artificial skin and method for evaluating uv screening agent Shiseido Co., Ltd. (JP) 2001-11-21 EP disclosed
EP-1145707-A1 COMPOSITIONS FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 2001-10-17 EP disclosed
EP-0688559-B1 Skin anti-ageing composition SHISEIDO CO LTD (JP) 2001-06-20 EP disclosed
EP-1066816-A1 AGENTS PROMOTING LAMININ PRODUCTION IN SKIN CELLS SHISEIDO COMPANY LIMITED (JP) 2001-01-10 EP disclosed
US-6077520-A ANTI-AGING TOPICAL COMPOSITION INCLUDING AT LEAST ONE OF SULFONYLETHYLENEAMINE OR MERCAPTOSULFONYLETHYLENEAMINE COMPOUNDS OF GIVEN FORMULA AND SPECIFIED ULTRAVIOLET LIGHT PROTECTIVE AGENTS SHISEIDO COMPANY, LTD. (JP) 2000-06-20 US disclosed
JP-H09227351-A UV RAYS ABSORBING SKIN COSMETIC SHISEIDO CO LTD 1997-09-02 JP disclosed
EP-0688559-A1 Skin anti-ageing composition SHISEIDO COMPANY LIMITED (JP) 1995-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326984-A1 FRAGRANCES WITH CYCLOPROPYL STRUCTURE CBR3, CNR1, CBR1 ABCB1 2188/4885ABCG2 3174/4885ABCC1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.